Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Interest Income

Income earned on cash, deposits, and investments held by the company.

Pharming Group N.V.NASDAQ: PHAR

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $3.24M rose 435.9% year over year, ahead of the +27.1% change in trailing-twelve-month interest income. Over 3 fiscal years it compounded at +211.0% a year.

Context

  • Interest income amounted to 0.7% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +435.9% holds above the trailing-twelve-month pace of +27.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.24M— QoQ
Last fiscal yearDec 2025
$2.56M-56.9% YoY
LTMMar 2026
$4.38M+27.1% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+435.9%——
1 year-56.9%——
3-year CAGR+211.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.56M USD
Year-over-year change
-56.9%
4-year CAGR
+155.5%

Interest Income vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.1% is the 2nd highest of 9, against a peer median of -14.4%.
  • Interest income amounts to 1.2% of revenue for PHAR, versus a peer median of 6.3%.
PHAR Competitors
Interest Income for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$4.68B USD+6281.3%+60.7%0.5%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$89.99M USD-11.7%+56.9%9.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$25.8M USD-41.1%+50.6%39.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$12.81M USD-9.0%+39.8%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$10.88M USD-17.0%+64.0%33.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$9.82M USD-22.7%+27.7%1.0%
PHVSPharvaris N.V.LTM Sep 2026€5.68M EUR+0.7%——
PHARPharming Group N.V.LTM Mar 2026$4.38M USD+27.1%+211.0%1.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€852.58K EUR-60.2%+176.5%6.3%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD—+148.8%0.0%
Peer median (excluding PHAR) —-14.4%+58.8%6.3%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.